**Author details**

Abdullah Saeed Gozai Al-Ghamdi

Address all correspondence to: asgalghamdi@hotmail.com

Gastroenterology Unit, Medical Department, King Fahad Hospital, Jeddah, Saudi Arabia

### **References**


[24] Simonsen L, Kane A, et al. Unsafe injections in the developing world and transmis‐ sion of bloodborne pathogens: a review. Bull World Health Organ. 1999;77:789-800.

[8] Neumann AU, Lam NP, et al. Hepatitis C viral dynamics in vivo and the antiviral

[9] Xu Z, Choi J, et al. Hepatitis C virus F protein is a short-lived protein associated with

[10] McLauchlan J, Lemberg MK, et al. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002, 21:3980-3988.

[11] Carrere-Kremer S, Montpellier-Pala C, et al. Subcellular localization and topology of

[12] Yamaga AK, Ou JH. Membrane topology of the hepatitis C virus NS2 protein. J Biol

[13] Egger D, Wolk B, et al. Expression of hepatitis C virus proteins induces distinct mem‐ brane alterations including a candidate viral replication complex. J Virol

[14] Mottola G, Cardinali G, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Vi‐

[15] Tu H, Gao L, et al. Hepatitis C virus RNA polymerase and NS5A complex with a

[16] Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3

[17] Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol.

[18] Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol.

[20] Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hep‐ atitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol.

[21] Nelson PK, Mathers BM, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.

[22] Wasley A, Alter M. Epidemiology of hepatitis C: geographic differences and tempo‐

[23] Medhat A, Shehata M, et al. Hepatitis C in a community in Upper Egypt: risk factors

[19] Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21S-28S.

efficacy of interferon-alpha therapy. Science 1998;282:103-107.

the p7 polypeptide of hepatitis C virus. J Virol 2002;76:3720-3730.

the endoplasmic reticulum. J Virol 2003, 77:1578-1583.

Chem 2002;277:33228-33234.

2002;76:5974-5984

98 Recent Advances in Liver Diseases and Surgery

rology 2002;293:31-43.

Suppl 1):15S-20S.

1999;31(Suppl 1):9-16

1999;31(Suppl 1):17-24.

2005;51(1):31-46.

SNARE-like protein. Virology 1999;263:30-41.

ral trends. Semin Liver Dis. 2000;20:1-16.

for infection. Am J Trop Med Hyg. 2002;66:633-638.


[54] Prescribing Information for OLYSIOTM (simeprevir): Janssen Therapeutics, Division of Janssen Products, LP, Titusville NJ 08560. Issued November 2013.

[38] Ravaioli M, Grazi GL, et al. Liver transplantation with the Meld system: a prospec‐

[39] Asrani SK, Kim WR. Model for end-stage liver disease: end of the first decade. Clin

[40] National Medical Policy. FIBROSpect, FIBROSURE, ActiTest and Other Non-invasive

[41] Al-Ghamdi AS. Fibroscan®: a noninvasive test of liver fibrosis assessment. Saudi J

[42] Verveer C, de Knegt RJ. Non-invasive measurement of liver fibrosis: application of the FibroScan® in hepatology. Scand J Gastroenterol Suppl. 2006;243:85-8.

[43] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C.

[44] Ziol M, Handra-Luca A, et al. Non-invasive assessment of liver fibrosis by measure‐ ment of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41:48-54.

[45] Palacios PA, Salmerón EJ. Role of liver biopsy in the diagnosis and management of

[46] Foster GR. A Guide to PEGylation, Pharmacokinetics and Pegylated Interferons. Ro‐

[47] Glue P, Fang JWS, et al. Pegylated interferon-[alpha]2b: pharmacokinetics, pharma‐ codynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther.

[48] Jacobson IM, McHutchison JG, et al. Telaprevir for previously untreated chronic hep‐

[49] Sherman KE, Flamm SL, et al. Response-guided telaprevir combination treatment for

[50] Zeuzem S, Andreone P, et al. Telaprevir for retreatment of HCV infection. N Engl J

[51] Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV gen‐

[52] Bacon BR, Gordon SC, et al. Boceprevir for previously treated chronic HCV genotype

[53] Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the

The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.

chronic hepatitis C. Gastroenterol Hepatol. 2007;30(7):402-407.

atitis C virus infection. N Engl J Med. 2011;364:2405-2416.

otype 1 infection. N Engl J Med. 2011;364:1195-1206.

1 infection. N Engl J Med. 2011;364:1207-1217.

Liver. Can J Gastroenterol.2012;26:359-375.

hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.

che; Basel, Switzerland: 2003. Better by Design.

tive study from a single European center. Am J Transplant. 2006;6:1572.

Liver Dis. 2011;15:685.

100 Recent Advances in Liver Diseases and Surgery

2000;68:556-67.

Med. 2011;364:2417-2428.

Gastroenterol 2007;13:147-149.

Testing for Liver Fibrosis. 2014, health net.


[81] Gane EJ, Stedman CA, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146:736-743.

[67] Jacobson IM, Gordon SC, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients

[68] Kowdley KV, Lawitz E, et al. Sofosbuvir with pegylated interferon alfa-2a and riba‐ virin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100-2107.

[69] Lawitz E, Poordad F, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatolo‐

[70] Lawitz E, Mangia A, et al. Sofosbuvir for previously untreated chronic hepatitis C in‐

[71] Svarovskaia ES, Dvory-Sobol H, et al. Infrequent development of resistance in geno‐ type 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3

[72] Osinusi A, Meissner EG, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JA‐

[73] Lawitz E, Poordad FF, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with geno‐ type 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2

[74] Sulkowski MS, Naggie S, et al. Sofosbuvir and ribavirin for hepatitis C in patients

[75] Yoshida EM, Sulkowski MS, et al. Concordance of sustained virologic response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C vi‐

[76] Zeuzem S, Dusheiko GM, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

[77] Sulkowski MS, Gardiner DF, et al. Daclatasvir plus sofosbuvir for previously treated

[78] HARVONI® (ledipasvir and sofosbuvir)-Gilead Sciences, Inc. http:// www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvo‐

[79] Afdhal N, Reddy KR, et al. Ledipasvir and sofosbuvir for previously treated HCV

[80] Afdhal N, Zeuzem S, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1

or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221.

genotype 1 infection. N Engl J Med. 2014;370:1483-1493.

infection. N Engl J Med. 2014;370:1889-1898.

without treatment options. N Engl J Med. 2013;368:1867-77.

gy. 2015;769-775.

102 Recent Advances in Liver Diseases and Surgery

MA. 2013;310:804-11.

trial. Lancet. 2014;383:515-523.

rus. Hepatology. 2014;61:41-45.

N Engl J Med. 2014;370:1993-2001.

ni\_pi.pdf.

fection. N Engl J Med. 2013;368:1878-87.

clinical trials. Clin Infect Dis. 2014;15:1666-1674.

with HIV coinfection. JAMA. 2014;312:353-361.

